Navigation Links
Promising new neuroimaging techniques for early detection of Alzheimer's disease
Date:1/29/2010

Amsterdam, January 29, 2010 Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease. The study is published in the current issue of the Journal of Alzheimer's Disease.

Lanzoprazole and astemizole specifically tag pathological oligomers of tau which form the core of neurofibrillary tangles (NFTs), a pathognomonic brain lesion in Alzheimers patients. Prof. Dr. R.B. Maccioni and Dr. Leonel Rojo, authors of the study commented, "Since neurofibrillary tangles are positively correlated with cognitive impairment, we propose that these drugs have great potential in PET neuroimaging for in vivo early detection of AD and in reducing the formation of NFTs. These studies, based on advanced proteomics and databases of molecular interactions, may help to find potential new drugs for early diagnosis and treatment of Alzheimers disease. The findings are the result of a long-standing research program supported by the Alzheimers Association-USA and Fondecyt, Chile to evaluate new drug candidates." Technological applications of this discovery are being developed with the collaboration of VentureL@b of the Universidad Adolfo Ibaez.

Interestingly, lanzoprazole and astemizole, already approved for treatment of proton pump disorders and as an antihistamine respectively, specifically bind directly to aggregated variants of tau protein, paired helical filaments (PHFs) and NFTs in Alzheimers brains. Until now it has not been possible to detect these pathological brain structures in living Alzheimers patients. The only confirmation of the disease has been attained by postmortem neuropathological evaluation.

Dr. Maccioni and Dr. Rojo postulate that "This important discovery will provide the stepping stone for the development of new specific neuroimaging technologies based on PET radiotracers that monitor the formation and growth of NFTs in patients during the course of their lives."

The interactions of lanzoprazole and astemizole with the anomalous tau aggregates were assessed by classical radioligand assays, combined with surface plasmon resonance, bioinformatic approaches and immunofluorescence studies on isolated PHFs and brain samples from Alzheimer's cases. The affinity of these for tau aggregates was significantly higher than that of polymers of the amyloid- peptide according to SPR analysis. This is relevant since senile plaques are abundant but not pathognomonic in AD patients. Immunochemical studies on PHFs from brains of AD patients and SPR studies confirm these findings. The capacity of all these drugs to penetrate the blood-brain barrier was confirmed by either in vitro studies using parallel artificial membrane permeability assays or in vivo by pharmacokinetic studies comparing distribution profiles in blood and brain in mice.


'/>"/>

Contact: Esther Mateike
e.mateike@iospress.n
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... During ... campus, Standard Process Inc. awarded $6,000 in chiropractic scholarships. The winners ... Each student is in her fifth trimester of classes at Logan. , “Standard ...
(Date:5/23/2016)... ... 2016 , ... Four Circles Recovery Center, a leading treatment center that offers ... launch of its new extended care program, Fifth Circle. Available for clients between the ... another primary treatment program, Fifth Circle is designed to foster the recovery process of ...
(Date:5/23/2016)... ... 23, 2016 , ... VitreosHealth is presenting a free online webinar entitled, ‘GlobalHealth: ... 12:00 PM ET. To register, click here . , The webinar ... on Big Data with a new predictive and prescriptive analytics paradigm. During the ...
(Date:5/23/2016)... ... ... announced today the upcoming airing of Innovations with Ed ... 2016 at 4:00pET via Fox Business. , The show ... innovation to safely and rapidly develop cures for mosquito-borne, ...
(Date:5/23/2016)... ... May 23, 2016 , ... "Pro3rd Vibes gives FCPX users ... any project," said Christina Austin - CEO of Pixel Film Studios. , Pro3rd ... Final Cut Pro X. Pixel Film Studios’ minimalistic presets allow users to add a ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... -- Cellvizio Highlighted in Physician Presentations ... and 91 st Congress of the Japan ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... its Cellvizio platform is being highlighted at two ... month of May. The first meeting highlighting Cellvizio ...
(Date:5/19/2016)... -- A new report published by Allied ... Forecasts, 2015 -2022, projects that the world medical imaging ... CAGR of 5.1% from 2015 to 2022. X-ray imaging ... revenue-generating segment throughout the forecast period. North ... market share in 2015, and is expected to dominate ...
(Date:5/19/2016)... 2016 At the 18 th ... Amsterdam , (May 15-19), Elekta announced that ... system available, has been used in the treatment of ... vascular malformations and functional disorders. Today, Gamma ... every year in hundreds of leading hospitals and clinics ...
Breaking Medicine Technology: